Hormonal
Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.
If you have both T2DM and obesity, or just T2DM, you may get more cardiovascular benefits and fewer side effects from Tirzepatide than if you have obesity alone. This suggests that your specific health condition plays a role in how well the medication works for you. Discuss your specific health profile with your doctor to understand what to expect.
Compared to obesity, patients with T2DM experienced greater benefits of MACE-4... and lower risk of TAEs... TZP 15mg was more effective in reducing ACD and SAEs, but also increased the risk of discontinuation. among patients who use TZP, T2DM patients had greater benefits in ACD and less risk of SAEs and DAEs compared to obesity patients.
Why this rating
Based on subgroup analysis of a Bayesian network meta-analysis of 14 RCTs.
Source
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis
xuyang gong et al. · Research Square · 2024
DOI 10.21203/rs.3.rs-4159026/v1
More from this paper
- Tirzepatide (TZP) reduces the risk of four-component major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes (T2DM) and obesity compared to placebo, with the 15mg dose showing the most significant reduction.Good
- Tirzepatide increases the risk of total adverse events (TAEs) and adverse events leading to discontinuation (DAEs) in a dose-dependent manner, with the 15mg dose having the highest risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →